Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy

Drugs and Aging

Volumn 33, Issue 10, 2016, Pages 685-697

  Liu, Jing ^a   Yang, Bin ^a   Ke, Jun ^a   Li, Wenjia ^a   Suen, Wen Chen ^a  

^a Sunshine Lake Pharma Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; BAPINEUZUMAB; BISPECIFIC ANTIBODY; EPITOPE; GANTENERUMAB; GSK 933776; MONOCLONAL ANTIBODY; MONOMER; OLIGOMER; PONEZUMAB; SOLANEZUMAB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); FIBER; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN POLYMORPHISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; AGING; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PLAQUE, AMYLOID; PRECLINICAL STUDY; PROTEIN AGGREGATION, PATHOLOGICAL; TREATMENT OUTCOME;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; PLAQUE, AMYLOID; PROTEIN AGGREGATION, PATHOLOGICAL; TREATMENT OUTCOME;

EID: 84989835415     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-016-0406-x     Document Type: Review

References (112)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s Dement J Alzheimer’s Assoc. 2007;3:186–91.
2. Alzheimer’s disease—global drug forecast and market analysis to 2023. GlobalData PharmaPoint. Reference code: GDHC010EPIDR. Publication data: May 2015.
3. Geldmacher DS. Treatment guidelines for Alzheimer’s disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry. 2007;9:113–21.
4. Pozueta J, Lefort R, Shelanski ML. Synaptic changes in Alzheimer’s disease and its models. Neuroscience. 2013;251:51–65.
5. Hane F, Tran G, Attwood SJ, Leonenko Z. Cu(2+) affects amyloid-beta (1–42) aggregation by increasing peptide-peptide binding forces. PLoS One. 2013;8:e59005.
6. Fu HJ, Liu B, Frost JL, Lemere CA. Amyloid-beta immunotherapy for Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2010;9:197–206.
7. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448–52.
8. Kayed R, Lasagna-Reeves CA. Molecular mechanisms of amyloid oligomers toxicity. J Alzheimer’s Dis. 2013;33(Suppl 1):S67–78.
9. Goure WF, Krafft GA, Jerecic J, Hefti F. Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics. Alzheimers Res Ther. 2014;6:42.
10. Cole SL, Vassar R. The Alzheimer’s disease beta-secretase enzyme, BACE1. Mol Neurodegener. 2007;2:22.
11. Hamley IW. The amyloid beta peptide: a chemist’s perspective. Role in Alzheimer’s and fibrillization. Chem Rev. 2012;112:5147–92.
12. Dong X, Chen W, Mousseau N, Derreumaux P. Energy landscapes of the monomer and dimer of the Alzheimer’s peptide Abeta(1–28). J Chem Phys. 2008;128:125108.
13. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, et al. Assembly and aggregation properties of synthetic Alzheimer’s A4/beta amyloid peptide analogs. J Biol Chem. 1992;267:546–54.
14. Jang S, Shin S. Computational study on the structural diversity of amyloid beta peptide (abeta(10–35)) oligomers. J Phys Chem B. 2008;112:3479–84.
15. Miller Y, Ma B, Nussinov R. Polymorphism of Alzheimer’s Abeta17–42 (p3) oligomers: the importance of the turn location and its conformation. Biophys J. 2009;97:1168–77.
16. Tjernberg LO, Callaway DJ, Tjernberg A, Hahne S, Lilliehook C, Terenius L, et al. A molecular model of Alzheimer amyloid beta-peptide fibril formation. J Biol Chem. 1999;274:12619–25.
17. Miller Y, Ma B, Nussinov R. Polymorphism in Alzheimer Abeta amyloid organization reflects conformational selection in a rugged energy landscape. Chem Rev. 2010;110:4820–38.
18. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci. 1998;95:6448–53.
19. Zhang Y, Lyubchenko YL. The structure of misfolded amyloidogenic dimers: computational analysis of force spectroscopy data. Biophys J. 2014;107:2903–10.
20. Spencer RK, Li H, Nowick JS. X-ray crystallographic structures of trimers and higher-order oligomeric assemblies of a peptide derived from Abeta(17–36). J Am Chem Soc. 2014;136:5595–8.
21. Du J, Murphy RM. Characterization of the interaction of beta-amyloid with transthyretin monomers and tetramers. Biochemistry. 2010;49:8276–89.
22. Barrera Guisasola EE, Gutierrez LJ, Andujar SA, Angelina E, Rodriguez AM, Enriz RD. Pentameric models as alternative molecular targets for the design of new antiaggregant agents. Curr Protein Pept Sci. 2016;17:156–68.
23. Tran L, Basdevant N, Prevost C, Ha-Duong T. Structure of ring-shaped Abeta42 oligomers determined by conformational selection. Sci Rep. 2016;6:21429.
24. Strodel B, Lee JW, Whittleston CS, Wales DJ. Transmembrane structures for Alzheimer’s Abeta(1–42) oligomers. J Am Chem Soc. 2010;132:13300–12.
25. Gessel MM, Wu C, Li H, Bitan G, Shea JE, Bowers MT. Abeta(39–42) modulates Abeta oligomerization but not fibril formation. Biochemistry. 2012;51:108–17.
26. Sherman MA, Lesne SE. Detecting abeta*56 oligomers in brain tissues. Methods Mol Biol. 2011;670:45–56.
27. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, et al. Globular amyloid beta-peptide oligomer—a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem. 2005;95:834–47.
28. Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, et al. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry. 2006;45:15157–67.
29. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci. 2003;26:267–98.
30. Hoshi M, Sato M, Matsumoto S, Noguchi A, Yasutake K, Yoshida N, et al. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc Natl Acad Sci. 2003;100:6370–5.
31. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, et al. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999;274:25945–52.
32. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer’s disease. Nature. 2008;451:720–4.
33. Tu S, Okamoto S, Lipton SA, Xu H. Oligomeric Abeta-induced synaptic dysfunction in Alzheimer’s disease. Mol Neurodegener. 2014;9:48.
34. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, et al. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci. 2008;28:4231–7.
35. Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, et al. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J. 2008;27:224–33.
36. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci. 2007;27:796–807.
37. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature. 2002;418:291.
38. Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci. 2009;106:14745–50.
39. Morozova OA, Gupta S, Colby DW. Prefibrillar huntingtin oligomers isolated from HD brain potently seed amyloid formation. FEBS Lett. 2015;589:1897–903.
40. Walker LC, Jucker M. Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci. 2015;38:87–103.
41. Lee HG, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA. Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther. 2007;321:823–9.
42. Mandrekar-Colucci S, Landreth GE. Microglia and inflammation in Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2010;9:156–67.
43. Spangenberg EE, Green KN. Inflammation in Alzheimer’s disease: lessons learned from microglia-depletion models. Brain Behav Immun. 2016. doi:10.1016/j.bbi.2016.07.003.
44. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, et al. Neurotoxicity of Alzheimer’s disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J. 2010;29:3408–20.
45. Morrone CD, Liu M, Black SE, McLaurin J. Interaction between therapeutic interventions for Alzheimer’s disease and physiological Abeta clearance mechanisms. Front Aging Neurosci. 2015;7:64.
46. Paul S, Planque S, Nishiyama Y. Beneficial catalytic immunity to abeta peptide. Rejuvenation Res. 2010;13:179–87.
47. Lichtlen P, Mohajeri MH. Antibody-based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem. 2008;104:859–74.
48. Robert R, Lefranc MP, Ghochikyan A, Agadjanyan MG, Cribbs DH, Van Nostrand WE, et al. Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid beta peptide. Mol Immunol. 2010;48:59–72.
49. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci. 1997;94:4109–12.
50. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916–9.
51. Sil S, Ghosh A, Ghosh T. Impairment of blood brain barrier is related with the neuroinflammation induced peripheral immune status in intracerebroventricular colchicine injected rats: an experimental study with mannitol. Brain Res. 2016;1646:278–86.
52. Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin Biol Ther. 2010;10:1121–30.
53. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005;25:629–36.
54. DiFrancesco JC, Longoni M, Piazza F. Anti-Abeta autoantibodies in amyloid related imaging abnormalities (ARIA): candidate biomarker for immunotherapy in Alzheimer’s disease and cerebral amyloid angiopathy. Front Neurol. 2015;6:207.
55. Miles LA, Crespi GA, Doughty L, Parker MW. Bapineuzumab captures the N-terminus of the Alzheimer’s disease amyloid-beta peptide in a helical conformation. Sci Rep. 2013;3:1302.
56. clinicaltrials.gov. A service of the U.S. National Institutes of Health. https://www.clinicaltrials.gov/. Accessed 09 Sep 2016.
57. Bagyinszky E, Youn YC, An SS, Kim S. The genetics of Alzheimer’s disease. Clin Interv Aging. 2014;9:535–51.
58. Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE. Evidence for impaired amyloid beta clearance in Alzheimer’s disease. Alzheimers Res Ther. 2013;5:33.
59. Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, et al. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8:18.
60. Wisniewski T, Goni F. Immunotherapeutic approaches for Alzheimer’s disease. Neuron. 2015;85:1162–76.
61. Delnomdedieu M, Duvvuri S, Li DJ, Atassi N, Lu M, Brashear HR, et al. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease. Alzheimers Res Ther. 2016;8:12.
62. Moreth J, Mavoungou C, Schindowski K. Passive anti-amyloid immunotherapy in Alzheimer’s disease: what are the most promising targets? Immun Ageing. 2013;10:18.
63. Leyhe T, Andreasen N, Simeoni M, Reich A, von Arnim CA, Tong X, et al. Modulation of beta-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I study. Alzheimers Res Ther. 2014;6:19.
64. Volz C, Pauly D. Antibody therapies and their challenges in the treatment of age-related macular degeneration. Eur J Pharm Biopharm. 2015;95:158–72.
65. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci. 2001;98:8850–5.
66. Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol. 2014;76:185–205.
67. Lundkvist J, Halldin MM, Sandin J, Nordvall G, Forsell P, Svensson S, et al. The battle of Alzheimer’s Disease—the beginning of the future unleashing the potential of academic discoveries. Front Pharmacol. 2014;5:102.
68. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–21.
69. Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimer’s Dement J Alzheimer’s Assoc. 2016;12:110–20.
70. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006;26:5340–6.
71. Miyoshi I, Fujimoto Y, Yamada M, Abe S, Zhao Q, Cronenberger C, et al. Safety and pharmacokinetics of PF-04360365 following a single-dose intravenous infusion in Japanese subjects with mild-to-moderate Alzheimer’s disease: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study. Int J Clin Pharmacol Ther. 2013;51:911–23.
72. Bogstedt A, Groves M, Tan K, Narwal R, McFarlane M, Hoglund K. Development of immunoassays for the quantitative assessment of amyloid-beta in the presence of therapeutic antibody: application to pre-clinical studies. J Alzheimer’s Dis. 2015;46:1091–101.
73. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimer’s Dis. 2012;28:49–69.
74. Shughrue PJ, Acton PJ, Breese RS, Zhao WQ, Chen-Dodson E, Hepler RW, et al. Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiol Aging. 2010;31:189–202.
75. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, et al. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem. 2007;100:23–35.
76. Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J, et al. Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Abeta oligomers. Mol Neurodegener. 2010;5:57.
77. Sarsoza F, Saing T, Kayed R, Dahlin R, Dick M, Broadwater-Hollifield C, et al. A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol. 2009;118:505–17.
78. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486–9.
79. Morgado I, Wieligmann K, Bereza M, Ronicke R, Meinhardt K, Annamalai K, et al. Molecular basis of beta-amyloid oligomer recognition with a conformational antibody fragment. Proc Natl Acad Sci. 2012;109:12503–8.
80. Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM. Structure-based design of conformation- and sequence-specific antibodies against amyloid beta. Proc Natl Acad Sci. 2012;109:84–9.
81. Westwood M, Lawson ADG. Opportunities for conformation-selective antibodies in amyloid-related diseases. Antibodies 2015;4:170–96.
82. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2006;2:99–119.
83. Larson ME, Lesne SE. Soluble Abeta oligomer production and toxicity. J Neurochem. 2012;120(Suppl 1):125–39.
84. Barghorn S, Striebinger A, Giaisi S, Koehler A, Ebert U, Hillen H. Abeta-oligomer selective antibody A-887755 exhibits a favorable profile for Alzheimer’s disease immunotherapy compared to Abeta-peptide unselective antibodies. Alzheimer’s Dementia. 2009;5:424.
85. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci. 2012;32:9677–89.
86. Cummings J. Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, et al. A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer’s disease. In: Alzheimer’s association international conference 2014, Copenhagen, Presentation number: O4-11-062014.
87. Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer’s disease mice. Neuron. 2012;76:908–20.
88. Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, et al. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7:e32014.
89. Lannfelt L, Moller C, Basun H, Osswald G, Sehlin D, Satlin A, et al. Perspectives on future Alzheimer therapies: amyloid-beta protofibrils—a new target for immunotherapy with BAN2401 in Alzheimer’s disease. Alzheimers Res Ther. 2014;6:16.
90. Tucker S, Moller C, Tegerstedt K, Lord A, Laudon H, Sjodahl J, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimer’s Disease. 2015;43:575–88.
91. Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, et al. Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. 2016;8:14.
92. Nerelius C, Laudon H, Sigvrdson J. Improved Aβ protofibril binding antibodies. WIPO Patent Application WO/2016/005466. International Publication Data, 14 Jan 2016.
93. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113:3716–25.
94. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Muller R, Nimmrich V, et al. Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci. 2010;30:10369–79.
95. Krafft GA, Hefti F, Goure WF, Jerecic J, Iverson K. ACU-193: A drug candidate antibody that selectively targets soluble Abeta oligomers. Alzheimer’s Dementia. 2013;9:326.
96. Neurimmune. RTM™ Technology Platform. http://www.neurimmune.com/-technology/rtm-technology-platform-.html. Accessed 08 Sep 2016.
97. Thierry B, Paul HW, Thomas E, Kenneth R, Joseph A, Fang Q, et al. A method of reducing brain amyloid plaques using anti-Aβ antibodies. WIPO Patent Application WO/2014/089500. International Publication Data, 12 June 2014.
98. Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. 2016;537:50–6.
99. ® 2015. Available 22 July 2015.
100. Lannfelt L, Relkin NR, Siemers ER. Amyloid-ss-directed immunotherapy for Alzheimer’s disease. J Intern Med. 2014;275:284–95.
101. Jia Q, Deng Y, Qing H. Potential therapeutic strategies for Alzheimer’s disease targeting or beyond beta-amyloid: insights from clinical trials. BioMed Res Int. 2014;2014:837157.
102. Relkin N. Clinical trials of intravenous immunoglobulin for Alzheimer’s disease. J Clin Immunol. 2014;34(Suppl 1):S74–9.
103. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368:387–403.
104. da Rocha MD, Viegas FP, Campos HC, Nicastro PC, Fossaluzza PC, Fraga CA, et al. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer’s disease. CNS Neurol Disord Drug Targets. 2011;10:251–70.
105. Dias KS, Viegas C Jr. Multi-target directed drugs: a modern approach for design of new drugs for the treatment of Alzheimer’s disease. Curr Neuropharmacol. 2014;12:239–55.
106. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:84ra44.
107. Gadkar K, Yadav DB, Zuchero JY, Couch JA, Kanodia J, Kenrick MK, et al. Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain. Eur J Pharm Biopharm. 2016;101:53–61.
108. Miller TW, Messer A. Intrabody applications in neurological disorders: progress and future prospects. Mol Ther. 2005;12:394–401.
109. de Marco A. Recombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needs. Microb Cell Fact. 2015;14:125.
110. LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G. The Alzheimer’s A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet. 1995;9:21–30.
111. Paganetti P, Calanca V, Galli C, Stefani M, Molinari M. beta-site specific intrabodies to decrease and prevent generation of Alzheimer’s Abeta peptide. J Cell Biol. 2005;168:863–8.
112. Moran N. Mouse platforms jostle for slice of humanized antibody market. Nat Biotechnol. 2013;31:267–8.